KZIA Profile
Kazia Therapeutics Limited, headquartered in Sydney, Australia, operates as a prominent biotechnology firm specializing in oncology research and drug development. Originally established as Novogen Limited and rebranded as Kazia Therapeutics Limited in November 2017, the company boasts a robust pipeline focused on advancing novel therapies for challenging cancers.
Central to Kazia Therapeutics' portfolio is Paxalisib, its lead development candidate. Paxalisib is a potent small molecule designed to penetrate the blood-brain barrier, targeting the PI3K/Akt/mTor pathway implicated in glioblastoma, a highly aggressive form of brain cancer. The drug's innovative mechanism of action positions it as a promising therapy for patients facing limited treatment options.
In addition to Paxalisib, Kazia Therapeutics is advancing EVT801, an investigational new drug with broad potential applications across various cancer types. This initiative underscores the company's commitment to pioneering therapeutic solutions that address unmet medical needs and improve patient outcomes globally.
Driven by a commitment to scientific innovation and clinical excellence, Kazia Therapeutics continues to expand its research capabilities and strategic partnerships. With a focus on rigorous clinical trials and regulatory compliance, the company aims to accelerate the development and commercialization of its pipeline candidates, further solidifying its position at the forefront of oncology biotechnology.
|
